Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cognitive Deficits in Schizophrenia Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

NCT01959594
View directory record Official record
Conditions
Healthy
Interventions
3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562, PF-06412562 TBD mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 2 Interventional

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

NCT01163227
View directory record Official record
Conditions
Schizophrenia Disorders
Interventions
Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Glendale, California • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 2 Interventional

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

NCT04822883
View directory record Official record
Conditions
Cognitive Impairment, Schizophrenia
Interventions
RL-007, RL-007 Matching Placebo
Drug
Lead sponsor
Recognify Life Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

NCT01095562
View directory record Official record
Conditions
Cognitive Deficits in Schizophrenia
Interventions
ABT-126, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
20 Years to 55 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Cerritos, California • Costa Mesa, California • Escondido, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

NCT01012167
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Galantamine, Placebo-Oxytocin, Placebo-Galantamine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

NCT00487942
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
12
States / cities
Garden Grove, California • National City, California • Paramount, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

NCT04972227
View directory record Official record
Conditions
Schizophrenia
Interventions
CY6463, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 1 Interventional

Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia

NCT01394471
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Intranasal Oxytocin Spray
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

NCT05136690
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
Nicotine patch, MK-4334, Placebo patch, Placebo capsule
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 7, 2026, 3:57 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

NCT00604760
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
MEM 3454, Placebo for MEM 3454
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
44
States / cities
Lemon Grove, California • Newport Beach, California • Oceanside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2008 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia

NCT00423943
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
modafinil, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 54 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

NCT00492336
View directory record Official record
Conditions
Schizophrenia
Interventions
rasagiline (Pharmacodynamics), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 7, 2026, 3:57 AM EDT
Terminated Phase 2 Interventional Results available

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

NCT02855411
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia (CIAS)
Interventions
PF-04958242, placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
16
States / cities
Garden Grove, California • Oceanside, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Not applicable Interventional Results available

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

NCT00963924
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Placebo, Cognitive Remediation
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

CRT-Guanfacine for SPD

NCT02524899
View directory record Official record
Conditions
Schizotypal Personality Disorder, SPD
Interventions
Cognitive Remediation Therapy, Guanfacine, Placebo
Behavioral · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 7, 2026, 3:57 AM EDT
Completed No phase listed Observational

The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders

NCT03166098
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Cognitive Function Assessments
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 30 Years
Enrollment
139 participants
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A D1 Agonist For Working Memory

NCT02507206
View directory record Official record
Conditions
Schizotypal Personality Disorder, SPD
Interventions
DAR 0-100A, Placebo
Drug
Lead sponsor
Antonia New
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

NCT06225115
View directory record Official record
Conditions
Cognitive Dysfunction, Schizophrenia
Interventions
KYN-5356, placebo
Drug
Lead sponsor
Kynexis B.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 7, 2026, 3:57 AM EDT
Not listed Phase 4 Interventional

Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia

NCT01012830
View directory record Official record
Conditions
Schizophrenia, Dementia
Interventions
Huperzine A
Drug
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 59 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2009 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia

NCT01773239
View directory record Official record
Conditions
Schizophrenia
Interventions
TARA computer-based exercises
Behavioral
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

NCT01749098
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-04958242, Ketamine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Varenicline Adjunctive Treatment in Schizophrenia

NCT00492349
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia

NCT00061789
View directory record Official record
Conditions
Schizophrenia
Interventions
SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 7, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

Biomarkers in Schizophrenia

NCT00817336
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
D Serine, Placebo
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 7, 2026, 3:57 AM EDT